Detecting Epidermal Growth Factor Receptor Tumor Activity In Vivo During Cetuximab Therapy of Murine Gliomas

Summer Gibbs, Kimberley S. Samkoe, Julia A. O'Hara, Scott C. Davis, P. Jack Hoopes, Tayyaba Hasan, Brian W. Pogue

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Rationale and Objectives: Noninvasive molecular imaging of glioma tumor receptor activity was assessed with diagnostic in vivo fluorescence monitoring during targeted therapy. The study goals were to assess the range of use for treatment monitoring and stratification of tumor types using epidermal growth factor (EGF) receptor (EGFR) status with administration of fluorescently labeled EGF and determine its utility for tumor detection compared to magnetic resonance imaging (MRI). Materials and Methods: EGFR+ and EGFR- glioma tumor lines (human glioma [U251-GFP] and rat gliosarcoma [9L-GFP], respectively) were used to assess these goals, having a 20-fold difference between their EGF uptakes. Results: Treatment with cetuximab in the EGFR+ tumor-bearing animals led to decreased EGF tumor uptake, whereas for the EGFR- tumors, no change in fluorescence signal followed treatment. This diagnostic difference in EGFR expression could be used to stratify the tumor-bearing animals into groups of potential responders and nonresponders, and receiver-operating characteristic curve analysis revealed an area under the curve (AUC) of 0.92 in separating these tumors. The nonlocalized growth pattern of U251-GFP tumors resulted in detection difficulty on standard MRI, but high EGFR expression made them detectable by fluorescence imaging (AUC = 1.0). The EGFR+ U251-GFP tumor-bearing animals could be noninvasively stratified into treated and untreated groups on the basis of fluorescence intensity difference (P = .035, AUC = 0.90). Conclusions: EGFR expression was tracked in vivo with fluorescence and determined to be of use for the stratification of EGFR+ and EGFR- tumors, the detection of EGFR+ tumors, and monitoring of molecular therapy.

Original languageEnglish (US)
Pages (from-to)7-17
Number of pages11
JournalAcademic Radiology
Volume17
Issue number1
DOIs
StatePublished - Jan 2010
Externally publishedYes

Fingerprint

Epidermal Growth Factor Receptor
Glioma
Neoplasms
Therapeutics
Fluorescence
Epidermal Growth Factor
Area Under Curve
Cetuximab
Gliosarcoma
Magnetic Resonance Imaging
Molecular Imaging
Optical Imaging
ROC Curve

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Detecting Epidermal Growth Factor Receptor Tumor Activity In Vivo During Cetuximab Therapy of Murine Gliomas. / Gibbs, Summer; Samkoe, Kimberley S.; O'Hara, Julia A.; Davis, Scott C.; Hoopes, P. Jack; Hasan, Tayyaba; Pogue, Brian W.

In: Academic Radiology, Vol. 17, No. 1, 01.2010, p. 7-17.

Research output: Contribution to journalArticle

Gibbs, Summer ; Samkoe, Kimberley S. ; O'Hara, Julia A. ; Davis, Scott C. ; Hoopes, P. Jack ; Hasan, Tayyaba ; Pogue, Brian W. / Detecting Epidermal Growth Factor Receptor Tumor Activity In Vivo During Cetuximab Therapy of Murine Gliomas. In: Academic Radiology. 2010 ; Vol. 17, No. 1. pp. 7-17.
@article{82b01bbc74e14df0a9735df79e8ba154,
title = "Detecting Epidermal Growth Factor Receptor Tumor Activity In Vivo During Cetuximab Therapy of Murine Gliomas",
abstract = "Rationale and Objectives: Noninvasive molecular imaging of glioma tumor receptor activity was assessed with diagnostic in vivo fluorescence monitoring during targeted therapy. The study goals were to assess the range of use for treatment monitoring and stratification of tumor types using epidermal growth factor (EGF) receptor (EGFR) status with administration of fluorescently labeled EGF and determine its utility for tumor detection compared to magnetic resonance imaging (MRI). Materials and Methods: EGFR+ and EGFR- glioma tumor lines (human glioma [U251-GFP] and rat gliosarcoma [9L-GFP], respectively) were used to assess these goals, having a 20-fold difference between their EGF uptakes. Results: Treatment with cetuximab in the EGFR+ tumor-bearing animals led to decreased EGF tumor uptake, whereas for the EGFR- tumors, no change in fluorescence signal followed treatment. This diagnostic difference in EGFR expression could be used to stratify the tumor-bearing animals into groups of potential responders and nonresponders, and receiver-operating characteristic curve analysis revealed an area under the curve (AUC) of 0.92 in separating these tumors. The nonlocalized growth pattern of U251-GFP tumors resulted in detection difficulty on standard MRI, but high EGFR expression made them detectable by fluorescence imaging (AUC = 1.0). The EGFR+ U251-GFP tumor-bearing animals could be noninvasively stratified into treated and untreated groups on the basis of fluorescence intensity difference (P = .035, AUC = 0.90). Conclusions: EGFR expression was tracked in vivo with fluorescence and determined to be of use for the stratification of EGFR+ and EGFR- tumors, the detection of EGFR+ tumors, and monitoring of molecular therapy.",
author = "Summer Gibbs and Samkoe, {Kimberley S.} and O'Hara, {Julia A.} and Davis, {Scott C.} and Hoopes, {P. Jack} and Tayyaba Hasan and Pogue, {Brian W.}",
year = "2010",
month = "1",
doi = "10.1016/j.acra.2009.07.027",
language = "English (US)",
volume = "17",
pages = "7--17",
journal = "Academic Radiology",
issn = "1076-6332",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - Detecting Epidermal Growth Factor Receptor Tumor Activity In Vivo During Cetuximab Therapy of Murine Gliomas

AU - Gibbs, Summer

AU - Samkoe, Kimberley S.

AU - O'Hara, Julia A.

AU - Davis, Scott C.

AU - Hoopes, P. Jack

AU - Hasan, Tayyaba

AU - Pogue, Brian W.

PY - 2010/1

Y1 - 2010/1

N2 - Rationale and Objectives: Noninvasive molecular imaging of glioma tumor receptor activity was assessed with diagnostic in vivo fluorescence monitoring during targeted therapy. The study goals were to assess the range of use for treatment monitoring and stratification of tumor types using epidermal growth factor (EGF) receptor (EGFR) status with administration of fluorescently labeled EGF and determine its utility for tumor detection compared to magnetic resonance imaging (MRI). Materials and Methods: EGFR+ and EGFR- glioma tumor lines (human glioma [U251-GFP] and rat gliosarcoma [9L-GFP], respectively) were used to assess these goals, having a 20-fold difference between their EGF uptakes. Results: Treatment with cetuximab in the EGFR+ tumor-bearing animals led to decreased EGF tumor uptake, whereas for the EGFR- tumors, no change in fluorescence signal followed treatment. This diagnostic difference in EGFR expression could be used to stratify the tumor-bearing animals into groups of potential responders and nonresponders, and receiver-operating characteristic curve analysis revealed an area under the curve (AUC) of 0.92 in separating these tumors. The nonlocalized growth pattern of U251-GFP tumors resulted in detection difficulty on standard MRI, but high EGFR expression made them detectable by fluorescence imaging (AUC = 1.0). The EGFR+ U251-GFP tumor-bearing animals could be noninvasively stratified into treated and untreated groups on the basis of fluorescence intensity difference (P = .035, AUC = 0.90). Conclusions: EGFR expression was tracked in vivo with fluorescence and determined to be of use for the stratification of EGFR+ and EGFR- tumors, the detection of EGFR+ tumors, and monitoring of molecular therapy.

AB - Rationale and Objectives: Noninvasive molecular imaging of glioma tumor receptor activity was assessed with diagnostic in vivo fluorescence monitoring during targeted therapy. The study goals were to assess the range of use for treatment monitoring and stratification of tumor types using epidermal growth factor (EGF) receptor (EGFR) status with administration of fluorescently labeled EGF and determine its utility for tumor detection compared to magnetic resonance imaging (MRI). Materials and Methods: EGFR+ and EGFR- glioma tumor lines (human glioma [U251-GFP] and rat gliosarcoma [9L-GFP], respectively) were used to assess these goals, having a 20-fold difference between their EGF uptakes. Results: Treatment with cetuximab in the EGFR+ tumor-bearing animals led to decreased EGF tumor uptake, whereas for the EGFR- tumors, no change in fluorescence signal followed treatment. This diagnostic difference in EGFR expression could be used to stratify the tumor-bearing animals into groups of potential responders and nonresponders, and receiver-operating characteristic curve analysis revealed an area under the curve (AUC) of 0.92 in separating these tumors. The nonlocalized growth pattern of U251-GFP tumors resulted in detection difficulty on standard MRI, but high EGFR expression made them detectable by fluorescence imaging (AUC = 1.0). The EGFR+ U251-GFP tumor-bearing animals could be noninvasively stratified into treated and untreated groups on the basis of fluorescence intensity difference (P = .035, AUC = 0.90). Conclusions: EGFR expression was tracked in vivo with fluorescence and determined to be of use for the stratification of EGFR+ and EGFR- tumors, the detection of EGFR+ tumors, and monitoring of molecular therapy.

UR - http://www.scopus.com/inward/record.url?scp=71049173751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71049173751&partnerID=8YFLogxK

U2 - 10.1016/j.acra.2009.07.027

DO - 10.1016/j.acra.2009.07.027

M3 - Article

C2 - 19796971

AN - SCOPUS:71049173751

VL - 17

SP - 7

EP - 17

JO - Academic Radiology

JF - Academic Radiology

SN - 1076-6332

IS - 1

ER -